REMAP-CAP
International adaptive platform trial specifically designed to be employed in a pandemic to evaluate multiple interventions simultaneously in critically ill patients.
Last updated
Was this helpful?
International adaptive platform trial specifically designed to be employed in a pandemic to evaluate multiple interventions simultaneously in critically ill patients.
Last updated
Was this helpful?
Population: Any patient admitted to critical care with CAP or COVID-19
Interventions: Multiple different treatment domains with differing eligibility criteria - see the website (or just get DREEAM to do it)
Comparison: Complicated! Varies by domain, however many treatments can be evaluated on a patient at a time with multiple randomisations.
Outcomes: All cause 90 day mortality, others vary depending on domain
All CAP or COVID patients should be entered onto the eligibility log using the trial website as inclusion and exclusion criteria vary from domain to domain. In summary please let DREEAM know about any potential patient and we will work out what the patient is eligible for.
Principle investigator: Dan Harvey
Trainee-lead: Ben Lowe
DREEAM: Megan Meredith
Glucocorticoids improve outcomes for hospitalized patients with COVID-19
Therapeutic anticoagulation is futile, and possibly harmful, in critically ill patients with COVID-19
Therapeutic anticoagulation improves outcomes in hospitalized patients with COVID-19 who are not admitted to an ICU with organ support
Convalescent plasma does not improve outcomes for critically ill patients with COVID -19.
Tocilizumab and Sarilumab reduce mortality and prevent progression to invasive mechanical ventilation or ECMO in critically ill patients with COVID-19
Lopinavir/ritonavir does not improve outcomes for critically ill patients with COVID-19.
Hydroxychloroquine does not improve outcomes, and potentially harms patients with COVID -19
Website:
There are some excellent educational resources and podcasts on the . These explain not only about the trial but about adaptive platform trials and Bayesian stats.
on a regular basis as each treatment meets its trigger for benefit or futility:
